NEW YORK--(BUSINESS WIRE)--FermaVir Pharmaceuticals, Inc. (the “Company”) (OTCBB:FMVR), announced today that RAB Special Situations (Master) Fund Limited has filed a Schedule 13G with the SEC disclosing an 8.3% equity interest in the Company as of January 4, 2007.
